As BCR::ABL-targeting TKIs, used with chemotherapy and corticosteroids, are the standard of care of BCR::ABL+ B-ALL, we were interested to test combinations of CEL_Amide with commercially available TKIs, including imatinib, dasatinib, nilotinib, and ponatinib, in BV-173 and TOM-1 cell lines. Here, ABL1 is linked to acute lymphoblastic leukemia.